1. Home
  2. PVL vs EQ Comparison

PVL vs EQ Comparison

Compare PVL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.86

Market Cap

60.7M

Sector

Energy

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.05

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
EQ
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.7M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PVL
EQ
Price
$1.86
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
107.4K
642.1K
Earning Date
03-20-2026
05-25-2026
Dividend Yield
7.72%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.29
52 Week High
$2.04
$2.70

Technical Indicators

Market Signals
Indicator
PVL
EQ
Relative Strength Index (RSI) 54.78 53.77
Support Level $1.75 $1.38
Resistance Level $1.89 $2.30
Average True Range (ATR) 0.07 0.19
MACD -0.00 -0.03
Stochastic Oscillator 25.00 62.86

Price Performance

Historical Comparison
PVL
EQ

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: